CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- FinancialsAltman Z-Score 3.93: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.23BCNY776.28M · vs all stocks (USD)
Revenue (TTM)
759.50MCNY112.80M · vs all stocks (USD)
Profit Margin
-17.90%Beta
0.4070xvs all stocks
52-Week Change
-0.20%vs all stocks
Market Capitalization
5.23BCNY776.28M · vs all stocks (USD)
Enterprise Value
5.06BCNY751.54M · vs all stocks (USD)
Forward P/E
32.94xPrice to Sales (TTM)
7.33xPrice to Book (MRQ)
3.20xEnterprise to Revenue
6.66xEnterprise to EBITDA
-178.45xGross Margin
55.01%Profit Margin
-17.90%Operating Margin
-2.99%Return on Assets (TTM)
-1.76%Return on Equity (TTM)
-6.94%Revenue (TTM)
759.50MCNY112.80M · vs all stocks (USD)
Revenue per Share (TTM)
0.7200CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-8.20%Gross Profit (TTM)
407.87MCNY60.58M · vs all stocks (USD)
EBITDA (TTM)
-28.36MCNY-4.21M · vs all stocks (USD)
Net Income (TTM)
-135.94MCNY-20.19M · vs all stocks (USD)
Operating Cash Flow (TTM)
34.79MCNY5.17M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
35.65MCNY5.29M · vs all stocks (USD)
5-Year Average Dividend Yield
0.82%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
8.18MCNYFY2025 · Dec 31, 2025Revenue
775.69MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
343.11MCNYFY2025 · Dec 31, 2025Gross Profit
432.58MCNYFY2025 · Dec 31, 2025Operating Income
-59.46MCNY-8.83M · vs all stocks (USD)
Pre-tax Income
-146.81MCNYFY2025 · Dec 31, 2025Income Tax Expense
-20.28MCNYFY2025 · Dec 31, 2025Net Income
-126.53MCNYFY2025 · Dec 31, 2025EBIT
-133.05MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.96MCNYFY2025 · Dec 31, 2025Research & Development
62.50MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
304.39MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.55MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
24.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
13.76MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1276CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1276CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.06BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.06BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-126.53MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-8.17MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-69.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
-107.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
881.39MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-126.53MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-8.66MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
49.27MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
15.94MCNYFY2025 · Dec 31, 2025Capital Expenditures
-37.84MCNYFY2025 · Dec 31, 2025Net Acquisitions
782.46KCNYFY2025 · Dec 31, 2025Purchase of Investments
-40.00MCNYFY2025 · Dec 31, 2025Sale of Investments
29.42MCNYFY2025 · Dec 31, 2025Other Investing Activity
-3.77MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-51.40MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
294.95MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-425.66MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-12.35MCNYFY2025 · Dec 31, 2025Other Financing Charges
25.09MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-117.96MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.06BSharesUpdated Aug 19, 2026Float Shares
697.66MSharesUpdated Aug 19, 2026% Held by Insiders
36.79%vs all stocks
% Held by Institutions
4.09%vs all stocks
Total Cash (MRQ)
919.68MCNY136.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.8710CNYUpdated Aug 19, 2026Total Debt (MRQ)
396.48MCNY58.89M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2253xCurrent Ratio (MRQ)
2.01xBook Value per Share (MRQ)
1.65CNYUpdated Aug 19, 2026Total Assets
2.57BCNY382.40M · vs all stocks (USD)
Total Current Assets
1.52BCNYFY2025 · Dec 31, 2025Total Liabilities
810.65MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
82.16MCNYFY2025 · Dec 31, 2025Total Current Liabilities
728.49MCNYFY2025 · Dec 31, 2025Cash Equivalents
667.81KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
926.06MCNYFY2025 · Dec 31, 2025Accounts Receivable
228.30MCNYFY2025 · Dec 31, 2025Inventory
161.33MCNYFY2025 · Dec 31, 2025Accounts Payable
93.48MCNYFY2025 · Dec 31, 2025Short-term Debt
314.82MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.06MCNYFY2025 · Dec 31, 2025Long-term Debt
58.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.06BCNYFY2025 · Dec 31, 2025Retained Earnings
-804.70MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.76BCNY262.00M · vs all stocks (USD)
52-Week Low
4.10CNYUpdated Aug 19, 202652-Week High
6.86CNYUpdated Aug 19, 202652-Week Change
-0.20%vs all stocks
Beta
0.4070xvs all stocks
50-Day MA
4.94CNYUpdated Aug 19, 2026200-Day MA
5.27CNYUpdated Aug 19, 2026Avg 10-Day Volume
31.37MSharesUpdated Aug 19, 2026Avg 30-Day Volume
35.05MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.1300CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.55Profit Margin: -0.18
Financial Health
Altman Z-Score 3.93: safe zoneNotable
Altman Z-Score: 3.93
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
ChemPartner Pharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Si-Bone Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beta Bionics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule